Sanifit Therapeutics

Sanifit Therapeutics is a spin-off company from the Universitat de les Illes Balears. The company is focused on treatments for progressive vascular calcification disorders. The lead candidate, SNF472, is a novel small molecule, and a selective and potent inhibitor of hydroxyapatite (HAP) crystallization, the final common pathway that leads to vascular calcification, in clinical development in End Stage Kidney Disease (ESKD) patients, calciphylaxis and peripheral artery disease (PAD).

  • CEO & co-Founder: Joan Perelló
  • Location: Palma de Mallorca (Balearic Islands) and San Diego (USA)
  • Website:
  • Acquisition: Vifor Pharma